Drug Trial Radar · NCT06727422
Efficacy of Rifaximin With NAC in IBS-D
Last checked: Nov 20, 2026Latest source record: Apr 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
225
Planned (sponsor's estimate)
Start
Feb 4, 2026
Primary completion
Aug 1, 2026
Study completion Jan 1, 2027
Sponsor
- Lead sponsor
- Mark Pimentel, MDAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 10, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to examine the effectiveness of using a combination of a drug, rifaximin and a dietary supplement, N-acetyl-L-cysteine (NAC), to treat patients with irritable bowel syndrome with diarrhea (IBS-D). Rifaximin is one of the standard treatments for IBS-D and is FDA approved. While rifaximin is safe and effective for treating symptoms in patients with IBS-D, many patients find that their symptoms may not completely resolve, or may come back after a period of time. This research study is designed to test the investigational use of a combination of rifaximin and NAC. The combination of rifaximin and NAC is not approved by the U.S. Food and Drug Administration (FDA) for the treatment of IBS-D, and the effects of taking both medications together are unknown. However, the two medications are approved for use separately, as detailed below. Rifaximin is the only antibiotic approved by the FDA for the treatment of IBS-D. Rifaximin (at a dose of 550 mg by mouth three times daily for 14 days) is approved by the FDA for the treatment of IBS-D. Rifaximin (at a dose of 200 mg per mouth three times daily for 3 days) is FDA approved for the treatment of traveler's diarrhea. Rifaximin at a dose of 200 mg per mouth three times daily is not approved by the FDA for the treatment of IBS-D. NAC is approved by the FDA to treat acetaminophen overdose (72-hour oral and 21-hour intravenous (IV) regimens), and for use in breaking up mucus in the lungs in patients with chronic obstructive pulmonary disease (COPD) and other lung conditions such as bronchitis. NAC is also available over-the-counter in 600 mg and 900 mg capsules as a dietary supplement, although over-the-counter use is not regulated by the FDA. This study will utilize the 600 mg dietary supplement capsules. The Investigators want to know if using a combination of rifaximin and NAC will give better results in decreasing IBS-D symptoms than using rifaximin alone. As NAC is used to break up mucus in the lungs, and the Investigators want to see if this can also break up the mucus layer in the small intestine, and therefore potentially increase the effectiveness of rifaximin. The Investigators will be testing 2 doses to determine which dose is most effective. participants are being asked to take part in this research study because participants were diagnosed with IBS-D.
Conditions
- IBS (Irritable Bowel Syndrome)
- IBS-D (Diarrhea-predominant)
Interventions
rifaximin 66mg + N-acetylcysteine 560mg three times dailyDrug
RNIB21 containing rifaximin 66mg + N-acetylcysteine 560mg three times daily
RNIB21 containing rifaximin 132mg + N-acetylcysteine 560mg three times dailyDrug
RNIB21 containing rifaximin 132mg + N-acetylcysteine 560mg three times daily
PlaceboDrug
placebo three times daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- stool consistencyTime frame: 2 weeks
- Abdominal painTime frame: 2 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cedars-Sinai Medical Center
Los Angeles, California · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.